- Sophisticated and difficult-to-counterfeit holography helps discern counterfeits.



- As the most preferred product, ZYDENA moves to counter the distribution of counterfeits.



Dong-A Pharmaceutical of South Korea introduced a new hologram on the outer packaging box of its own
developed erectile dysfunction treatment, Zydena, in order to more effectively deter counterfeiting.
The new holography shows a world map that appears to overlap with the initial two letters of Zydena. This
hologram symbolizes Zydena’s rise from a domestic new drug to a global one. Depending on the viewing
angle, the letters Z and Y appear to shrink or enlarge, visualizing Zydena’s characteristics as an erectile
dysfunction treatment. The new hologram is larger than the previous one, making it clearer and allowing for a
more sophisticated design.



In order to express a range of symbols in high definition and enhance security, the new holography adopts
nanoseal technology, which is state-of-the-art technology currently used only for note issues or important
national projects. The hologram is exquisitely structured, making it difficult to mimic, which in turn makes
discernment between real Zydena and counterfeits easier.



Zydena is building a strong track record around the world and is now sold in 32 countries. Export agreements
now total 300 million dollars. In Russia, it is sold under the same brand name, Zydena. In the US, Phase III
clinical trials have started for US FDA approval. Dong-A is also developing daily low-dose Zydena (one tablet
once a day) in order to make it a global new drug.



“At present, you can take Zydena without having to worry about counterfeits since there are none out there, but
in order to forestall any possibility of distribution of counterfeit Zydena, we have introduced the new hologram
with cutting-edge anti-counterfeit technology,” says the marketer of Zydena.



MenPower, a network of 14 urology clinics, conducted a five-month survey on 569 respondents of consumer
awareness and preference about erectile dysfunction treatments marketed in Korea last year. It found that a
majority (54 percent) of the 569 respondents who had used at least three kinds of treatments preferred Zydena.